I-Corps: Accelerating recombinant protein screening

I-Corps：加速重组蛋白筛选

• 批准号: 2328626
• 负责人: Danielle Tullman Ercek
• 金额: $ 5万
• 依托单位: Northwestern University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2328626&HistoricalAwards=false
• 关键词: Corps; Accelerating; recombinant; protein; screening

The broader impact/commercial potential of this I-Corps project is a bacterial protein expression system that can fully secrete proteins as a platform to produce high-purity, low-cost proteins for several industries that use recombinant proteins as ingredients for their products or as a therapeutic drug itself. Manufacturers of cosmetics, food products, biomaterials, and biopharmaceuticals may be interested. These industries require large quantities of high-quality recombinant proteins for various purposes such as drug development, cosmetic formulation, food production, and biomaterial fabrication. The use of a recombinant protein expression system that can fully secrete proteins could provide significant advantages in terms of scalability, reproducibility, and cost-effectiveness compared to traditional protein production methods. Therefore, this technology can help them streamline their production processes and improve the quality of their products. The industries supported are creating products that improve sustainability and human health and thus a platform that can allow companies to produce these products faster and more economically would benefit all of society. This I-Corps project is based on the development of a bacterial protein expression platform that can fully secrete recombinant proteins. Engineering successes have been able to produce secreted proteins at commercially relevant titers. Purity levels of the system far exceed those of legacy protein expression systems and some applications may not require any additional protein purification to reach commercially required purity levels. Recovering a soluble product from the culture medium also avoids refolding or solubilizing proteins which can often result in loss of protein yields but is required when manufacturing proteins using other bacterial production hosts. These improvements will decrease overall production costs of protein-based products or products that use protein or enzyme precursors. The platform combines the fast growth, simple engineering, and low cost of traditional bacterial protein production systems with the simpler purification and product recovery of other, more complex, production hosts. This allows for fast production of high purity, soluble proteins while reducing costs of goods and speeding development timelines.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力是一种细菌蛋白表达系统，可以完全分泌蛋白质作为一种平台，用于为多个使用重组蛋白作为其产品的成分或治疗药物本身生产高纯度，低成本蛋白的平台。化妆品，食品，生物材料和生物制药的制造商可能感兴趣。这些行业需要大量的高质量重组蛋白，以进行各种目的，例如药物开发，化妆品配方，食品生产和生物材料制造。与传统蛋白质生产方法相比，使用可以完全分泌蛋白质的重组蛋白表达系统可以在可伸缩性，可重现性和成本效益方面具有显着优势。因此，这项技术可以帮助他们简化生产过程并提高产品质量。所支持的行业正在创建改善可持续性和人类健康的产品，因此可以使公司更快，更经济地生产这些产品的平台将使整个社会受益。 这个I-Corps项目基于可以完全分泌重组蛋白的细菌蛋白表达平台的开发。工程成功已经能够在商业相关的滴度上产生分泌的蛋白质。系统的纯度水平远远超过了传统蛋白表达系统的纯度水平，某些应用可能不需要任何额外的蛋白质纯化即可达到商业要求的纯度水平。从培养基中回收可溶性产品还可以避免重新折叠或溶解蛋白质，这通常会导致蛋白质产量的损失，但在使用其他细菌生产宿主生产蛋白质时是必需的。这些改进将降低使用蛋白质或酶前体的基于蛋白质的产品或产品的总体生产成本。该平台将传统细菌蛋白质生产系统的快速增长，简单的工程和低成本结合在一起，并更简单的纯化和产品回收其他，更复杂的生产宿主。这允许快速生产高纯度，可溶性蛋白质，同时降低商品成本并加快开发时间表。该奖项反映了NSF的法定任务，并使用基金会的知识分子优点和更广泛的影响评估标准，认为值得通过评估来获得支持。